RS55511B1 - Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprema i upotreba - Google Patents

Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprema i upotreba

Info

Publication number
RS55511B1
RS55511B1 RS20161055A RSP20161055A RS55511B1 RS 55511 B1 RS55511 B1 RS 55511B1 RS 20161055 A RS20161055 A RS 20161055A RS P20161055 A RSP20161055 A RS P20161055A RS 55511 B1 RS55511 B1 RS 55511B1
Authority
RS
Serbia
Prior art keywords
propyl
disease
sulfate salt
pharmaceutically acceptable
diisobutylamino
Prior art date
Application number
RS20161055A
Other languages
English (en)
Serbian (sr)
Inventor
Stéphane Burlet
Cécilia Estrella
Mathieu Barrier
Patricia Melnyk
Nicolas Sergeant
Luc Buee
Philippe Verwaerde
Original Assignee
Alzprotect
Inst Nat Sante Rech Med
Université De Lille 2 Droit Et Santé
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alzprotect, Inst Nat Sante Rech Med, Université De Lille 2 Droit Et Santé filed Critical Alzprotect
Publication of RS55511B1 publication Critical patent/RS55511B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20161055A 2012-12-27 2013-12-27 Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprema i upotreba RS55511B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306690 2012-12-27
EP13815780.5A EP2938597B1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
PCT/EP2013/078068 WO2014102339A1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Publications (1)

Publication Number Publication Date
RS55511B1 true RS55511B1 (sr) 2017-05-31

Family

ID=47501005

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20161055A RS55511B1 (sr) 2012-12-27 2013-12-27 Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprema i upotreba

Country Status (23)

Country Link
US (3) US9562018B2 (enExample)
EP (1) EP2938597B1 (enExample)
JP (1) JP6384923B2 (enExample)
KR (1) KR102115060B1 (enExample)
CN (1) CN105008333B (enExample)
AU (2) AU2013369288B2 (enExample)
BR (1) BR112015015474B1 (enExample)
CA (1) CA2895285C (enExample)
DK (1) DK2938597T3 (enExample)
ES (1) ES2605494T3 (enExample)
HR (1) HRP20161612T2 (enExample)
HU (1) HUE030930T2 (enExample)
IL (1) IL239450B (enExample)
LT (1) LT2938597T (enExample)
MX (1) MX363367B (enExample)
NZ (1) NZ708959A (enExample)
PL (1) PL2938597T3 (enExample)
PT (1) PT2938597T (enExample)
RS (1) RS55511B1 (enExample)
RU (1) RU2655454C2 (enExample)
SI (1) SI2938597T1 (enExample)
WO (1) WO2014102339A1 (enExample)
ZA (1) ZA201504521B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS55511B1 (sr) * 2012-12-27 2017-05-31 Alzprotect Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprema i upotreba
WO2016146655A1 (en) 2015-03-16 2016-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
CN116249693A (zh) * 2020-10-01 2023-06-09 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺的琥珀酸盐，其制备及其用途
DK4225306T3 (da) * 2020-10-07 2025-03-24 Alzprotect Anvendelse af n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-aminsulfatsalte og solvater heraf til behandling af motorneuronsygdomme og neuromuskulære forbindelseslidelser
MX2024007691A (es) 2021-12-20 2024-07-01 Alzprotect Uso de sales de succinato de n-(3-(4-(3-(diisobutilamino)propil)pi perazin-1-il)propil)-1h-benzo[d]imidazol-2-amina y solvatos del mismo para el tratamiento de enfermedades de las neuronas motoras y trastornos de la union neuromuscular.
US20250205226A1 (en) 2022-03-25 2025-06-26 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
WO1998056423A1 (fr) * 1997-06-12 1998-12-17 Transgene S.A. Nouveaux complexes lipidiques pour le transfert d'au moins une substance therapeutiquement active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
HK1038749A1 (zh) 1998-09-30 2002-03-28 纽罗根公司 2-哌嗪烷基氨苯并吡咯衍生物:多巴胺受体亚型特异配体
WO2002096431A1 (en) * 2001-05-25 2002-12-05 The Regents Of The University Of California Optically active compounds clearing malformed proteins
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
EP1581517B1 (en) * 2002-12-23 2007-02-21 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
ATE524181T1 (de) * 2004-11-10 2011-09-15 Inst Nat Sante Rech Med Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
RS55511B1 (sr) * 2012-12-27 2017-05-31 Alzprotect Sulfatne soli n-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amina, njihova priprema i upotreba

Also Published As

Publication number Publication date
US20170151235A1 (en) 2017-06-01
US20190381036A1 (en) 2019-12-19
AU2013369288A8 (en) 2015-07-16
HUE030930T2 (hu) 2017-06-28
DK2938597T3 (en) 2017-01-09
US9562018B2 (en) 2017-02-07
ZA201504521B (en) 2016-11-30
NZ708959A (en) 2019-11-29
SI2938597T1 (sl) 2017-03-31
HRP20161612T2 (hr) 2017-02-24
MX2015008502A (es) 2015-12-16
IL239450A0 (en) 2015-07-30
BR112015015474B1 (pt) 2022-04-19
AU2018202218A1 (en) 2018-04-26
RU2655454C2 (ru) 2018-05-29
BR112015015474A2 (enExample) 2017-08-15
ES2605494T3 (es) 2017-03-14
US20160108003A1 (en) 2016-04-21
US10537569B2 (en) 2020-01-21
CN105008333A (zh) 2015-10-28
HRP20161612T1 (hr) 2017-01-27
US10772884B2 (en) 2020-09-15
KR20150105313A (ko) 2015-09-16
MX363367B (es) 2019-03-20
CA2895285C (en) 2021-03-30
AU2018202218B2 (en) 2019-02-21
EP2938597B1 (en) 2016-10-26
JP6384923B2 (ja) 2018-09-05
LT2938597T (lt) 2017-01-25
RU2015130671A (ru) 2017-01-30
EP2938597A1 (en) 2015-11-04
IL239450B (en) 2018-06-28
HK1215582A1 (en) 2016-09-02
AU2013369288B2 (en) 2018-02-22
AU2013369288A1 (en) 2015-07-02
CA2895285A1 (en) 2014-07-03
PL2938597T3 (pl) 2017-03-31
CN105008333B (zh) 2018-02-09
WO2014102339A1 (en) 2014-07-03
PT2938597T (pt) 2016-12-09
KR102115060B1 (ko) 2020-05-25
JP2016503813A (ja) 2016-02-08

Similar Documents

Publication Publication Date Title
AU2018202218B2 (en) Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl) -1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
DK2958916T3 (en) Solid forms of a selective CDK4 / 6 inhibitor
AU2009288037B2 (en) Novel choline cocrystal of epalrestat
TW202106680A (zh) Glyt1抑制劑之固體形式
JP2024056724A (ja) ムスカリン性アセチルコリン受容体アゴニストの結晶性多形
WO2013134371A1 (en) Methods and compounds to be used in the treatment of neurodegenerative diseases
KR102881188B1 (ko) N-(3-(4-(3-(다이이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민의 석시네이트 염, 이의 제조 및 용도
HK1215582B (en) Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
US20180273507A1 (en) Crystal forms of a m1 receptor positive allosteric modulator
NZ710138B2 (en) Solid forms of a selective cdk4/6 inhibitor
JP2011522016A (ja) ４−ブロモフェニル１，４−ジアザビシクロ［３．２．２］ノナン−４−カルボキシラートのフマル酸塩、この結晶形態、調製、および治療的使用